RT Journal Article
SR Electronic
T1 Dysregulated immune responses in COVID-19 patients correlating with disease severity and invasive oxygen requirements
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.14.21263541
DO 10.1101/2021.09.14.21263541
A1 García-González, Paulina
A1 Tempio, Fabián
A1 Fuentes, Camila
A1 Merino, Consuelo
A1 Vargas, Leonardo
A1 Simon, Valeska
A1 Ramirez-Pereira, Mirliana
A1 Rojas, Verónica
A1 Tobar, Eduardo
A1 Landskron, Glauben
A1 Araya, Juan Pablo
A1 Navarrete, Mariela
A1 Bastias, Carla
A1 Tordecilla, Rocío
A1 Varas, Macarena A.
A1 Maturana, Pablo
A1 Marcoleta, Andrés E.
A1 Allende, Miguel L.
A1 Naves, Rodrigo
A1 Hermoso, Marcela A.
A1 Salazar-Onfray, Flavio
A1 Lopez, Mercedes
A1 Bono, María Rosa
A1 Osorio, Fabiola
YR 2021
UL http://medrxiv.org/content/early/2021/09/17/2021.09.14.21263541.abstract
AB The prognosis of severe COVID-19 patients has motivated research communities to uncover mechanisms of SARS-CoV-2 pathogenesis also on a regional level. In this work, we aimed to understand the immunological dynamics of severe COVID-19 patients with different degrees of illness, and upon long-term recovery.We analyzed immune cellular subsets and SARS-CoV-2-specific antibody isotypes of 66 COVID-19 patients admitted to the Hospital Clínico Universidad de Chile, which were categorized according to the WHO ten-point clinical progression score. These included 29 moderate patients (score 4-5) and 37 severe patients under either high flow oxygen nasal cannula (18 patients, score 6), or invasive mechanical ventilation (19 patients, score 7-9), plus 28 convalescent patients and 28 healthy controls. Furthermore, six severe patients that recovered from the disease were longitudinally followed over 300 days.Our data indicate that severe COVID-19 patients display increased frequencies of plasmablasts, activated T cells and SARS-CoV-2-specific antibodies compared to moderate and convalescent patients. Remarkably, within the severe COVID-19 group, patients rapidly progressing into invasive mechanical ventilation show higher frequencies of plasmablasts, monocytes, eosinophils, Th1 cells and SARS-CoV-2-specific IgG than patients under high flow oxygen nasal cannula. These findings demonstrate that severe COVID-19 patients progressing into invasive mechanical ventilation show a distinctive type of immunity. In addition, patients that recover from severe COVID-19 begin to regain normal proportions of immune cells 100 days after hospital discharge and maintain high levels of SARS-CoV-2-specific IgG throughout the study, which is an indicative sign of immunological memory. Thus, this work can provide a useful benchmark for improvement of disease outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the COVID-19 research program of the National Agency for Research and Development (ANID), grant No 0752. FO is supported by an International Research Scholar grant from HHMI (HHMI#55008744) a FONDECYT grant No. 1200793, and ECOS-CONICYT grant (ECOS180052). MRB is supported by a FONDECYT grant No 1191438. PGG is supported by a postdoctoral fellowship from ANID, grant No 3190856. MA is supported by ANID/FONDAP/15200002. GL is supported by an ANID-postdoctoral fellowship, grant No 3190931. FSO is supported by the Millennium Science Initiative from the Ministry for the Economy, Development and Tourism (P09/016-F). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and the corresponding authors had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards at Hospital Clinico Universidad de Chile and at the Faculty of Medicine, Universidad de Chile (Protocol ID. Number 1151/20 and Protocol ID. Number No 074-2020). All patients and healthy controls were required to understand the study and sign an informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable